Mobotinib, a new treatment for specific lung cancer mutations

Mobocertinib (Mobocertinib), whose trade name is Exkivity, is an innovative third-generation tyrosine kinase inhibitor (TKI) developed by Japan's Takeda Pharmaceutical Co., Ltd. The drug is designed to treat patients with non-small cell lung cancer (NSCLC) who carry EGFR (epidermal growth factor receptor) exon 20 insertion mutations. EGFRMutation is an important factor driving the development of some lung cancers, which can lead to abnormal proliferation and survival of cancer cells.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases. Based on cell type, NSCLC can be further subdivided into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. It is worth noting that EGFR mutations are relatively common in NSCLC, especially in female patients who have never smoked. However, exon 20insertion mutations, as a rare and difficult-to-treat mutation type, often show resistance to traditional EGFR targeted therapies.

The mechanism of action of Mobotinib is that it irreversibly binds to and inhibits the tyrosine kinase activity of EGFR, thereby blocking the signaling pathways of cancer cells and inhibiting the growth and spread of tumors. In particular, it has a significant effect on EGFRexon 20 insertion mutations, allowing it to still have an inhibitory effect on tumors even when traditional EGFR inhibitor treatments are ineffective. Therefore, mobosetinibprovides a new treatment option for NSCLC patients with this particular type of mutation.

In 2021, based on the significant efficacy and safety data demonstrated in clinical trials, the U.S. Food and Drug Administration (FDA) accelerated the approval of mobosetinib (mobosetinib)For the treatment of NSCLC patients carrying EGFRexon20 insertion mutations. Clinical trial results show that Mobotinib can significantly extend the progression-free survival of patients and achieve complete or partial tumor response in some cases.